Use of a Comprehensive Frailty Assessment to Predict Morbidity in Patients with Multiple Myeloma undergoing Transplant

摘要

Multiple myeloma (MM) is a disease of aging adults and autologous stem cell transplant (ASCT) is considered the standard of care. As the population ages a growing number of older adults will undergo ASCT and an objective approach to estimate physiologic reserve and transplant morbidity risk is warranted. Here, we evaluate assess p16^INK4a (p16), a molecular aging biomarker, along with geriatric metrics to determine risk of transplant toxicity.MethodsWe prospectively evaluated 100 MM patients for frailty before and after ASCT using a Geriatric Assessment (GA) and collected T-cells for analysis of p16 using a custom nanostring codeset.